China Biologic Named to Forbes Magazine's Fifth Annual List of Asia's '200
Best Under a Billion'
TAI'AN CITY, China, Oct. 21 /PRNewswire-Asia-FirstCall/ -- China Biologic
Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the
"Company"),
one of the leading plasma-based pharmaceutical companies in China, today
announced that the Company was named on Forbes Magazine's fifth annual list of
Asia's "200 Best Under a Billion" for the year 2009.
To assemble its Best Under a Billion for the Asia-Pacific region, Forbes
considered only listed entities with under $1 billion in sales that have
posted solid top and bottom-line gains and appear to be headed for more. The
200 Asia-Pacific companies were selected based on their: profitability,
growth,
modest indebtedness and future prospects this year (for a more precise
methodology, go online to http://www.forbes.com/BUB ). According to Forbes,
this year's selection were survivors of unprecedented dislocations in the
global economy over the past 12 months, disrupted supply chains, frozen lines
of credit, depleted consumer coffers and business spending hibernation, who
seized opportunities rising from the economic uncertainty. China Biologic was
one of only 78 companies in China and Hong Kong to make the prestigious list.
"We are pleased that Forbes Magazine has recognized China Biologic as one
of the Asia-Pacific region's best small and mid-sized companies," said Mr.
Chao Ming Zhao, the Company's Chief Executive Officer. "We believe that this
accolade reflects our strong financial performance as well as our position as
the leading non-state owned, plasma-based biopharmaceutical company in China."
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned
subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing
Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an
Huitian Blood Products Co., Ltd., is currently the largest non-state-owned
plasma-based biopharmaceutical company in China. The Company is a fully
integrated biologic products company with plasma collection, production and
manufacturing, research and development, and commercial operations. The
Company's plasma-based biopharmaceutical products are irreplaceable during
medical emergencies, and are used for the prevention and treatment of various
diseases. The Company sells its products to hospitals and other healthcare
facilities in China. For more information please visit the Company's website
http://www.chinabiologic.com
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to
the business of China Biologic Products, Inc. and its subsidiary companies.
All statements, other than statements of historical fact included herein are
"forward-looking statements," including statements regarding: the significance
of the Company's recognition on Forbes Magazine's list of "Asia's 200 Best
Under a Billion" for the year 2009; the ability of the Company to achieve its
commercial objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of non-historical
information. These forward-looking statements are often identified by the use
of forward-looking terminology such as "believes," "expects" or similar
expressions, and involve known and unknown risks and uncertainties. Although
the Company believes that the expectations reflected in these forward-looking
statements are reasonable, they do involve assumptions, risks and
uncertainties, and these expectations may prove to be incorrect. Investors
should not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's actual results
could differ materially from those anticipated in these forward-looking
statements as a result of a variety of factors, including those discussed in
the Company's periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov ). All forward-
looking statements attributable to the Company or persons acting on its behalf
are expressly qualified in their entirety by these factors. Other than as
required under the securities laws, the Company does not assume a duty to
update these forward-looking statements.
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Tel: +86-538-6202206
Email: IR@chinabiologic.com
Web: http://www.chinabiologic.com
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY office)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgir.com
SOURCE China Biologic Products, Inc.
Mr. Y. Tristan Kuo, Chief Financial Officer of China Biologic Products, Inc.,
+86-538-6202206, IR@chinabiologic.com; or Investors, Crocker Coulson,
President of CCG Investor Relations, +1-646-213-1915,
crocker.coulson@ccgir.com, for China Biologic Products, Inc.
